Czech, Slovak Cancer Study to Use AdnaGen Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Scientists in the Czech Republic and Slovakia will use a breast cancer test from OncoVista Innovative Therapies subsidiary AdnaGen in a cancer research effort focused on using the predictive assay in clinics, the San Antonio-based firm said today.

Under the agreement, Tataa Molecular Diagnostics will partner with the Institute of Biotechnology of the Czech Academy of Science on the COHERTA study, which is funded in part through a grant from Hoffman-La Roche's Czech and Slovak subsidiaries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.